Cansortium Reports Third Quarter 2022 Financial Results
Cansortium Inc. reported Q3 2022 revenue of $22.1 million, a 42% increase YoY, and an Adjusted EBITDA of $11.7 million, more than double from a year ago. The company achieved a 71% growth in adjusted gross profit, totaling $16.7 million. Despite store closures due to Hurricane Ian, Cansortium anticipates continued expansion in Florida and Pennsylvania, with plans to enter Texas. However, revenue guidance for 2022 has been revised down to $85-$90 million from $90-$95 million. As of September 30, 2022, total debt stood at $69.4 million.
- Q3 2022 revenue increased 42% YoY to $22.1 million.
- Adjusted EBITDA reached a record $11.7 million, up 140% YoY.
- Adjusted gross profit grew by 71% to $16.7 million.
- Revenue guidance revised down to $85-$90 million from $90-$95 million.
- Q3 Revenue up
- Q3 Adjusted EBITDA up
MIAMI, Nov. 29, 2022 /PRNewswire/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced financial and operating results for the third quarter ended September 30, 2022. Unless otherwise indicated, all results are presented in U.S. dollars.
"We continued to execute on our profitability objectives during the third quarter, leading to another period of gross margin expansion and a record bottom line with strong cash flow generation," said CEO Robert Beasley. "Had it not been for Hurricane Ian driving store closures in late September, we would have generated our 11th consecutive quarter of revenue growth, so I am very pleased with our team's consistent effort to deliver on our goals."
"As we exit the year and look to 2023, we expect to continue opening new stores in Florida while driving organic growth in our three Pennsylvania dispensaries. We also have plans to begin building out our footprint in Texas and look forward to growing our presence in the state in 2023."
Q3 2022 Financial Highlights (vs. Q3 2021)
- Revenue increased
42% to$22.1 million compared to$15.6 million . - Florida revenue increased
39% to$18.2 million compared to$13.1 million . - Adjusted gross profit[1] increased
71% to$16.7 million or75.5% of revenue, compared to$9.8 million or62.7% of revenue. - Adjusted EBITDA increased
140% to a record$11.7 million or53.1% of revenue, compared to$4.9 million or31.3% of revenue. - Cash from operations increased significantly to
$5.4 million compared to cash used of$(4.2) million . - At September 30, 2022, the Company had approximately
$9.1 million of cash and cash equivalents and$69.4 million of total debt, with approximately 252.3 million fully diluted shares outstanding (based on treasury stock method and share price on September 30, 2022).
________________________ |
1 Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations. |
Operational Highlights
- In Florida, the Company anticipates opening one new store by the end of 2022 and an additional three stores in the first half of 2023. All of these locations are currently under contract and going through construction.
- During the third quarter, Cansortium temporarily closed twelve of its dispensaries in Florida during Hurricane Ian. All of the Company's stores reopened in October 2022.
- In Pennsylvania, the Company's newest dispensary in Annville is ramping and achieved a record month of sales in October 2022.
2022 Outlook
The Company has continued to make progress on its targeted initiatives focused on growth and long-term shareholder value creation and is revising its previously issued revenue projection for 2022. Cansortium now expects revenue for 2022 to range between
Conference Call
The Company will host a conference call and live audio webcast today at 4:30 p.m. Eastern time to discuss its financial and operational results, followed by a question-and-answer period.
Date: Tuesday, November 29, 2022
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10020760
Link: Cansortium Conference Call
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (720) 330-2829.
The conference call will also be available for replay via the News & Events section of the Company's investor relations website at https://investors.getfluent.com/.
About Cansortium Inc.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania and Texas. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium's unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.
Cansortium Inc.'s common shares trade on the CSE under the symbol "TIUM.U" and on the OTCQX Best Market under the symbol "CNTMF". For more information about the Company, please visit www.getfluent.com.
Forward-Looking Information
Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.
Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
For further information: www.getfluent.com.
CANSORTIUM INC. | ||||||
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | ||||||
As of September 30, 2022 and December 31, 2021 | ||||||
(USD '000) | ||||||
September 30, | December 31, | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ 9,099 | $ 9,024 | ||||
Trade receivable | 53 | 26 | ||||
Inventory, net | 10,621 | 8,981 | ||||
Biological assets | 4,713 | 3,297 | ||||
Investment held for sale | 200 | 200 | ||||
Prepaid expenses and other current assets | 1,772 | 2,007 | ||||
Total current assets | 26,458 | 23,535 | ||||
Property and equipment, net | 32,738 | 34,160 | ||||
Intangible assets, net | 94,674 | 95,822 | ||||
Right-of-use assets, net | 30,018 | 19,169 | ||||
Note receivable | - | 4,886 | ||||
Deposit | - | 2,727 | ||||
Goodwill | 1,526 | 1,526 | ||||
Other assets | 769 | 632 | ||||
Total assets | $ 186,182 | $ 182,457 | ||||
Liabilities | ||||||
Current liabilities | ||||||
Trade payable | 9,009 | 8,518 | ||||
Accrued liabilities | 8,080 | 5,846 | ||||
Income taxes payable | 10,173 | 2,120 | ||||
Derivative liabilities | 8,981 | 3,960 | ||||
Current portion of notes payable | 43 | 619 | ||||
Current portion of lease obligations | 2,014 | 2,500 | ||||
Total current liabilities | 38,300 | 23,563 | ||||
- | ||||||
Notes payable | 56,013 | 53,674 | ||||
Lease obligations | 33,233 | 21,091 | ||||
Deferred tax liability | 20,860 | 21,563 | ||||
Other long-term liabilities | 750 | - | ||||
Total liabilities | 149,156 | 119,891 | ||||
Shareholders' equity | ||||||
Share capital | 180,792 | 180,657 | ||||
Share-based compensation reserve | 6,329 | 6,176 | ||||
Equity conversion feature | 6,677 | 4,933 | ||||
Warrants | 28,939 | 28,869 | ||||
Accumulated deficit | (185,378) | (157,649) | ||||
Foreign currency translation reserve | (334) | (421) | ||||
Total shareholders' equity | 37,026 | 62,565 | ||||
Total liabilities and shareholders' equity | $ 186,182 | $ 182,457 |
CANSORTIUM INC. | ||||||||||
STATEMENT OF OPERATIONS | ||||||||||
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020 | ||||||||||
For the three months ended | For the nine months ended | |||||||||
2022 | 2021 | 2022 | 2021 | |||||||
Revenue, net of discounts | $ 22,100 | $ 15,568 | $ 64,228 | $ 47,153 | ||||||
Cost of goods sold | 5,419 | 5,805 | 20,990 | 16,956 | ||||||
Gross profit before fair value adjustments | 16,681 | 9,763 | 43,238 | 30,197 | ||||||
Fair value adjustments on inventory sold | (9,605) | (5,113) | (25,023) | (14,433) | ||||||
Unrealized gain on changes in fair value of biological assets | 2,558 | 6,113 | 13,224 | 11,768 | ||||||
Gross profit | 9,634 | 10,763 | 31,439 | 27,532 | ||||||
Expenses | ||||||||||
General and administrative | 2,188 | 2,084 | 7,348 | 8,241 | ||||||
Share-based compensation | 53 | 731 | 153 | 4,248 | ||||||
Sales and marketing | 4,556 | 4,033 | 12,833 | 11,094 | ||||||
Depreciation and amortization | 1,656 | 1,649 | 5,014 | 4,727 | ||||||
Total expenses | 8,453 | 8,497 | 25,348 | 28,310 | ||||||
(Loss) income from operations | 1,181 | 2,266 | 6,091 | (778) | ||||||
Other expense (income) | ||||||||||
Finance costs, net | 4,422 | 3,383 | 11,922 | 11,233 | ||||||
Loss (gain) on change in fair value of derivative liability | 313 | - | 5,021 | (1,551) | ||||||
Equity loss on investment in associate | - | - | - | - | ||||||
Private Placement issuance expense | - | 890 | - | 7,530 | ||||||
Loss on debt settlement | - | (10,794) | 1,136 | (42) | ||||||
Loss on disposal of assets | (22) | (20) | (22) | 30 | ||||||
Other (income) expense | (1) | 7 | (373) | (124) | ||||||
Total other expense | 4,712 | (6,534) | 17,684 | 17,076 | ||||||
Loss before income taxes | (3,531) | 8,800 | (11,593) | (17,854) | ||||||
Income tax expense | 2,026 | 1,437 | 7,542 | 4,868 | ||||||
Net income (loss) from continuing operations | (5,557) | 7,363 | (19,135) | (22,722) | ||||||
Net loss (income) from discontinued operations | 19 | 2 | 8,594 | 33 | ||||||
Net income (loss) | $ (5,576) | $ 7,361 | $ (27,729) | # | $ (22,755) | |||||
Other comprehensive gain that may be reclassified | ||||||||||
to profit or loss in subsequent years | ||||||||||
Exchange differences on translation of foreign operations and reporting currency | 62 | (22) | 87 | (33) | ||||||
Comprehensive income (loss) | $ (5,514) | $ 7,339 | $ (27,642) | # | $ (22,788) | |||||
Net income (loss) per share | ||||||||||
Basic and diluted - continuing operations | $ (0.02) | $ 0.03 | $ (0.11) | $ (0.10) | ||||||
Weighted average number of shares | ||||||||||
Basic number of shares | 252,276,742 | 248,405,314 | 252,230,588 | 221,637,004 | ||||||
Diluted number of shares | 309,136,061 | 303,101,057 | 308,192,639 | 265,312,794 | ||||||
CANSORTIUM INC. | ||
STATEMENTS OF CASH FLOWS | ||
(USD '000) | ||
For the nine months ended September 30, | ||
2022 | 2021 | |
Operating activities | ||
Net loss from continuing operations | $ (27,729) | $ (22,755) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Unrealized gain on changes in fair value of biological assets | (13,224) | (11,768) |
Realized gain on changes in fair value of biological assets | 25,023 | 14,433 |
Share-based compensation | 153 | 3,883 |
Depreciation and amortization | 9,534 | 7,529 |
Accretion and interest of convertible debentures | - | 3,457 |
Interest and debt issuance costs of term loan | 9,359 | - |
Interest income on notes receivable | (71) | - |
Loss on disposal of assets | (22) | 30 |
Loss on debt settlement | 1,136 | - |
Discontinued operations | 8,594 | 33 |
Change in fair market value of derivative | 5,021 | (1,551) |
Interest on lease liabilities | 2,546 | 1,911 |
Deferred tax expense | (703) | (852) |
Changes in operating assets and liabilities: | ||
Trade receivable | (27) | (153) |
Inventory | 1,185 | (4,969) |
Biological assets | (15,495) | (3,859) |
Prepaid expenses and other current assets | (477) | 1,632 |
Right of Use Assets/Liabilities | 236 | - |
Other assets | - | (122) |
Trade payable | 333 | (123) |
Accrued liabilities | 2,060 | (396) |
Income taxes payable | 8,053 | (9,553) |
Net cash provided by (used in) operating activities | 15,486 | (23,193) |
Investing activities | ||
Purchases of property and equipment | (5,439) | (15,210) |
Purchase of intangible assets | - | (318) |
Payment of notes receivable | 119 | 1,477 |
Proceeds from sale of property and equipment | - | 29 |
Advances for notes receivable | (94) | (1,802) |
Net cash used in investing activities | (5,414) | (15,824) |
Financing activities | ||
Proceeds from issuance of shares and warrants | - | 23,730 |
Proceeds from issuance of debt, net of loan issuance costs | - | 63,086 |
Proceeds from issuance of convertible debenture and warrants | 4,710 | - |
Payment of lease obligations | (4,226) | (3,342) |
Exercise of Options | 135 | - |
Exercise of warrants | - | 1,365 |
Principal repayments of notes payable | - | (35,373) |
Repayments of principal and interest of Senior Secure Term loan | (10,703) | - |
Net cash provided by (used in) financing activities | (10,084) | 49,466 |
Effect of foreign exchange on cash and cash equivalents | 87 | (33) |
Net increase (decrease) in cash and cash equivalents | 75 | 10,416 |
Cash and cash equivalents, beginning of period | 9,024 | 3,392 |
Cash and cash equivalents, end of period | $ 9,099 | $ 13,808 |
CANSORTIUM INC. | |||
ADJUSTED EBITDA RECONCILIATION | |||
(USD '000) | |||
Three months ended | |||
September | September | ||
30, 2022 | 30, 2021 | Variance | |
Net loss | $ (5,576) | $ 7,361 | $ (12,937) |
Finance costs, net | 4,422 | 3,383 | 1,039 |
Income taxes | 2,026 | 1,437 | 589 |
Depreciation and amortization | 3,464 | 2,844 | 620 |
EBITDA | $ 4,336 | $ 15,025 | $ (10,689) |
Three months ended | |||
September | September | Variance | |
EBITDA | $ 4,336 | $ 15,025 | $ (10,689) |
Change in fair value of biological assets | 7,047 | (1,000) | 8,047 |
Change in fair market value of derivative | 313 | - | 313 |
Loss on debt settlement | - | (10,794) | 10,794 |
Private placement issuance expense | - | 890 | (890) |
Share-based compensation | 53 | 731 | (678) |
Discontinued operations | 19 | 2 | 17 |
Loss on disposal of assets | (22) | (20) | (2) |
Other non-recurring expense/(income) | (1) | 52 | (53) |
Adjusted EBITDA | $ 11,745 | $ 4,886 | $ 6,859 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/cansortium-reports-third-quarter-2022-financial-results-301689408.html
SOURCE Cansortium Inc
FAQ
What was Cansortium's Q3 2022 revenue and its year-over-year growth?
How much did Cansortium's Adjusted EBITDA increase in Q3 2022?
What is the revised revenue guidance for Cansortium in 2022?
What operational challenges did Cansortium face in Q3 2022?
What are Cansortium's plans for expansion in 2023?
